Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 30, 2015 12:38 PM ET

Healthcare Providers and Services

Company Overview of 21st Century Oncology Holdings, Inc.

Company Overview

21st Century Oncology Holdings, Inc., together with its subsidiaries, operates as a physician-led provider of integrated cancer care services. Its radiation treatment services include external beam therapies, such as conformal radiation therapy, intensity modulated radiation therapy, and stereotactic radiosurgery, as well as internal radiation therapies, such as high-dose and low-dose rate brachytherapies. The company’s radiation treatment services also comprise image guided radiation therapy, Gamma function testing, and respiratory gating. In addition, it offers support services in the areas of psychological and nutritional counseling, as well as transportation assistance. Further, the comp...

2270 Colonial Boulevard

Fort Myers, FL 33907

United States

Founded in 1983

4,630 Employees

Phone:

239-931-7275

Key Executives for 21st Century Oncology Holdings, Inc.

Co-Founder, Chief Executive Officer, President, Executive Director, Member of Executive Committee, Member of Capital Allocation Committee, President of Radiation Therapy Services Inc. and Chief Executive Officer of Radiation Therapy Services Inc
Age: 62
Principal Financial Officers, Chief Accounting Officer, Senior Vice President, Corporate Controller and Assistant Treasurer
Age: 46
Chief Executive Officer of Medical Developers Cooperatief U A B V, Chief Executive Officer of Vidt Centro Medico, President of Medical Developers Cooperatief U A B V and President of Vidt Centro Medico
Age: 56
Chief Medical Officer
Age: 46
Chief Compliance Officer and Senior Vice President
Age: 63
Compensation as of Fiscal Year 2015.

21st Century Oncology Holdings, Inc. Key Developments

21st Century Oncology Holdings, Inc. Announces Auditor Changes

On August 25, 2015, 21st Century Oncology Holdings, Inc. notified Deloitte & Touche LLP that Deloitte was dismissed as the company's independent registered public accounting firm. Deloitte's dismissal became effective on August 25, 2015. On August 25, 2015, the company approved the engagement of Ernst & Young LLP as the company's new independent registered public accounting firm.

21st Century Oncology Holdings, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for Second Half and Full Year of 2015

21st Century Oncology Holdings, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, total revenues were $285,209,000 against $265,898,000 a year ago. Loss before income taxes was $59,375,000 against $203,665,000 a year ago. Net loss attributable to the company’s shareholder was $64,538,000 against $207,524,000 a year ago. Total pro-forma revenues $285,209,000 against $265,898,000 a year ago. Pro-forma Adjusted EBITDA was $51,099,000 against $43,197,000 a year ago. For the six months, total revenues were $563,692,000 against $499,295,000 a year ago. Loss before income taxes was $69,619,000 against $230,804,000 a year ago. Net loss attributable to the company’s shareholder $79,780,000 against $237,705,000 a year ago. Net cash provided by operating activities was $13,036,000 against $9,869,000 a year ago. Purchase of property and equipment was $25,753,000 against $33,147,000 a year ago. Total pro-forma revenues $563,692,000 against $508,114,000 a year ago. Pro-forma Adjusted EBITDA was $94,779,000 against $76,556,000 a year ago. For the second half of 2015, the company expects to have positive free cash flow defined as pro forma adjusted EBITDA less cash add-backs, interest payments, cash capital expenditures and cash taxes. For the full year 2015 the company expects pro forma adjusted EBITDA guidance between $182 million and $190 million. The capital expenditure guidance for the full year 2015 is approximately $45 million.

21st Century Oncology Holdings, Inc., Q2 2015 Earnings Call, Aug 12, 2015

21st Century Oncology Holdings, Inc., Q2 2015 Earnings Call, Aug 12, 2015

Similar Private Companies By Industry

Company Name Region
Topeka Intraoperative Monitoring, LLC United States
UnitedHealthcare of Pennsylvania, Inc. United States
Summa Physicians Inc. United States
TeamHealth Medical Call Center United States
Influence Inc United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
August 11, 2015
Unidad de Oncología Hospital Manuel Uribe de Envigado S.A.
Merger/Acquisition
April 21, 2015
Maddock Center for Radiation Oncology
Private Placement
September 26, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 21st Century Oncology Holdings, Inc., please visit www.rtsx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.